These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38939943)

  • 1. [Overview of new approaches to β-thalassemia treatment].
    Guo XF; Han L; Zhang XC; Zhang HH; Liu J
    Sheng Li Xue Bao; 2024 Jun; 76(3):496-506. PubMed ID: 38939943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
    Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
    Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
    Langer AL; Esrick EB
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
    Musallam KM; Rivella S; Taher AT
    Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
    [No Abstract]   [Full Text] [Related]  

  • 7. Beta Thalassemia: Monitoring and New Treatment Approaches.
    Khandros E; Kwiatkowski JL
    Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
    Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
    Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
    Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
    Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in treatment of thalassemia.
    El-Beshlawy A; El-Ghamrawy M
    Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Expert Overview on Therapies in Non-Transfusion-Dependent Thalassemia: Classical to Cutting Edge in Treatment.
    Saeidnia M; Fazeli P; Farzi A; Atefy Nezhad M; Shabani-Borujeni M; Erfani M; Tamaddon G; Karimi M
    Hemoglobin; 2023 Nov; 47(2):56-70. PubMed ID: 37325871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2021 update on clinical trials in β-thalassemia.
    Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
    Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
    Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
    Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on thalassemia intermedia.
    Maakaron JE; Cappellini MD; Taher AT
    J Med Liban; 2013; 61(3):175-82. PubMed ID: 24422369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
    Hamed EM; Meabed MH; Aly UF; Hussein RRS
    Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational drugs in phase I and phase II clinical trials for thalassemia.
    Motta I; Scaramellini N; Cappellini MD
    Expert Opin Investig Drugs; 2017 Jul; 26(7):793-802. PubMed ID: 28540737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety in thalassemia: lessons from the present and directions for the future.
    Grech L; Sultana J; Borg K; Borg J
    Expert Opin Drug Saf; 2021 Aug; 20(8):937-947. PubMed ID: 33877003
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging Therapies in β-Thalassemia.
    Bou-Fakhredin R; Kuo KHM; Taher AT
    Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.